Coherus Oncology Inc (CHRS) Q2 2024 Earnings Report

Coherus Oncology reported Q2 2024 revenue of $64.98 million, up 10.7% year over year, driven in part by biosimilar and specialty product movements. However, the quarter yielded a net loss of $12.92 million and an EBITDA loss of $6.40 million, with an operating loss of $20.51 million as the company continues to fund R&D and selling/general operations to advance its pipeline. Gross margin stood at 54.5%, reflecting a favorable product mix, while operating expenses remained elevated, resulting in an operating margin of −31.6% and a net margin of −19.9%. Notably, cash flow from operations was robust at approximately $59.7 million, contributing to a net decrease in cash of about $100.5 million for the period and ending cash of $159.2 million. The balance sheet shows total assets of $674.9 million against total liabilities of $758.9 million and negative stockholders’ equity of about $(84.1) million, underscoring the ongoing need for external capital or financing to fund ongoing development and commercialization activities. The company carries a substantial debt burden (total debt of $298.3 million) and a large working capital footprint, even as it generates operating cash flow through working capital movements. Management commentary on the QQ2 2024 results is not captured in the available transcript data, limiting the ability to quote direct management language in this analysis. The near-term thesis hinges on pipeline progression (e.g., CHS114, CHS1000, and other oncology assets) and the company’s ability to monetize partnerships and biosimilar franchises as the market for cancer therapeutics evolves.